GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...

GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...

Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC) has ...

LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...

GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

GSK posted higher profit as sales for its specialty treatments including HIV, cancer and asthma beat expectations, offsetting lower vaccine sales on weak demand in the U.S. GSK plans to bring five new ...

GSK said it is confident of achieving the top end of its full-year guidance after posting an increase in sales and profit for the second quarter, mainly driven by the strong performance of its ...

British drug maker GlaxoSmithKline, one of the Triangle’s largest employers, got a second-quarter boost from the post-Brexit decline of the British pound. The company also saw sales gains in its new ...

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market this ...

GSK GSK-1.70%decrease; red down pointing triangle raised its sales and earnings forecasts for the year after its specialty medicines business helped lift sales in the third quarter, the last reporting ...